The third quarter presented a challenging environment for the U.S. Biotin market, marked by constrained trading activity and persistent inventory imbalances that developed from earlier frontloading behaviour. The quarter began with elevated inventory levels as U.S. producers and importers had accelerated purchases in preceding periods to secure material ahead of anticipated tariff implementations. This frontloading activity created an overhang that dampened fresh procurement requirements, with many buyers indicating sufficient coverage for their operational needs. The excess inventory situation weighed on market dynamics and limited transaction urgency.
Price movements reflected these supply-demand imbalances, with quotations experiencing modest fluctuations rather than directional trends. A brief recovery materialized mid-quarter as some restocking activity emerged alongside improved consumer sentiment. However, this uptick proved temporary as cautious purchasing behaviour reasserted itself and buyers focused on working through existing stocks. Trade activity remained subdued throughout the period, with limited spot market engagement. Tariff implementations influenced market structure, providing some pricing support while reinforcing buyer hesitance toward large-scale commitments. Overall sentiment reflected uncertainty about demand trajectories as participants adopted wait-and-see approaches.
Analyst Insight
According to Procurement Resource, looking forward, Biotin prices are likely to remain stable as limited spot activity continues. However, anticipated new production capacity may introduce supply pressure into an already oversupplied U.S. market.